CHICAGO - Abbott Laboratories said Friday it would withdraw the diet drug Meridia, less than a month after it failed to win over a safety advisory panel of the U.S. Food and Drug Administration.
The FDA confirmed the North Chicago-based drug giant's decision, saying Abbott withdrew the drug because of "clinical trial data indicating an increased risk of heart attack and stroke."
The withdrawal of Meridia, also known by its scientific name sibutramine, leaves just one U.S.-approved diet drug on the market - the prescription Xenical.
"Meridia's continued availability is not justified when you compare the very modest weight loss that people achieve on this drug to their risk of heart attack or stroke," said Dr. John Jenkins, director of the FDA's Office of New Drugs in the agency's Center for Drug Evaluation and Research.
People are also reading…
"Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs," Jenkins said.
The FDA said the decision was voluntary. But many analysts believe the move came before the agency would have asked the company to remove it anyway in the face of intense criticism from consumer groups and mounting scrutiny by the Obama administration and members of Congress from both political parties on drug safety.
Last month, eight of 16 members of an FDA advisory panel said the drug should be withdrawn from the U.S. market. Meanwhile, six of the panelists said the drug should be prescribed only by "specially trained physicians" and include a strict FDA "black box" warning noting the new limits.
The other two panelists also said a new box warning should be added to alert consumers of increased risks of heart attacks and closer monitoring of patients by clinicians. None of the panelists among the Endocrinologic and Metabolic Drugs Advisory Committee said the drug should remain on the market with the labeling in its current form.
Meridia was approved by the FDA in November of 1997 for "weight loss and maintenance of weight loss in obese people, as well as in certain overweight people with other risks for heart disease," the FDA said. At the time, the agency said the approval "was based on clinical data showing that more people receiving sibutramine lost at least 5 percent of their body weight than people on placebo who relied on diet and exercise alone."
But a growing number of doctors and scientific experts said the risks of taking Meridia far outweighed the small weight loss patients might achieve.
Meridia has not been a big seller. Revenues from the pill have deteriorated amid criticism of its heart risks. Abbott has said it no longer promotes the drug in the U.S., where its sales are projected this year to be $30 million.
Prescription diet pills have had trouble winning respect with consumers and doctors because of safety issues and side effects. In 1997, a diet drug combination known as fen-phen was yanked from pharmacy shelves after it was linked to heart valve damage.
The U.S. Centers for Disease Control and Prevention estimates that two in three Americans are overweight.
